Global Diabetes Treatment Market

Diabetes Treatment Comprehensive Study by Diabetes Type (Type 1 Diabetes, Type 2 Diabetes), Device Type (Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors), Insulin Delivery Device (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Others)), Treatment Type (Insulin, Oral Hypoglycaemic Drugs, Non-Insulin Injectable Drugs, Other), Diabetes Test Type (Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test), Urine Test) Players and Region - Global Market Outlook to 2030

Diabetes Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11.98%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Diabetes Treatment
The diabetes is caused due to an increase in blood sugar level for a long period. This is due to either pancreas not producing enough insulin or cells of the body not responding to the insulin produced. Diabetes treatment provides a treatment for diabetes patient through insulin diet, oral hypoglycaemic drugs, non-insulin injectable drugs, and diabetes care therapies. Many regional governments have been taking many initiatives providing diabetes cure treatment, is fueling the growth of the market. Additionally, the rising number of developments and new launches of diabetes care devices have been supplementing the market. However, increasing health awareness, changing lifestyle and increasing adoption of yoga for diabetes cure are the limiting factors in the operating market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR11.98%


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.The Players having a strong hold in the market are Abbott Laboratories, Bayer AG, Eli Lily & Company, Medtronic, AstraZeneca Plc., Lifescan. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Diabetes Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Bayer AG (Germany), Eli Lily & Company (United States), Medtronic (United States), AstraZeneca Plc. (United Kingdom), Lifescan (United States), Terumo Medical Corporation (Japan), Roche Holding AG (Switzerland), Ascensia Diabetes Care Holdings AG (United States) and Becton Dickinson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Dexcom (United States), ARKRAY Healthcare Pvt. Ltd. (India), B. Braun Melsungen (Germany) and Terumo Corporation (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Diabetes Treatment market by and Region.



On the basis of geography, the market of Diabetes Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diabetes Type, the sub-segment i.e. Type 1 Diabetes will boost the Diabetes Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Device Type, the sub-segment i.e. Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors) will boost the Diabetes Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Insulin will boost the Diabetes Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diabetes Test Type, the sub-segment i.e. Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test) will boost the Diabetes Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Population Suffering from Diabetes due to Sedentary Lifestyle and Increasing Obese Population across the Globe

Market Growth Drivers:
Increasing Government Initiatives for Providing Diabetes Cure Treatment across the Globe and Rising Demand for Fast, Safe and Better Diabetes Care Products from Highly Populated Countries such as China and India

Challenges:
Adverse Effects Associated with Diabetes Care Devices

Restraints:
Low Awareness about the Diabetes Treatment in the Middle East Region and Increasing Adoption of Yoga for Diabetes Cure

Opportunities:
Rising International Research Collaboration for Diabetes Care Products and Treatment and Increasing Investment in Research and Development Activities lead to New Innovation

Market Leaders and their expansionary development strategies
In January 2024, The International Diabetes Federation (IDF) is delighted to announce the continuation of our partnership with P&G Health. Through our partnership, P&G Health will support IDF in developing an online course on Diabetes and Nerve Health for the IDF School of Diabetes Understanding Diabetes Platform.  
In March 2024, Theon Pharmaceutical launches Linagliptin + Dapagliflozin + Metformin Hydrochloride (SR) for type 2 diabetes management for the first time in India. Theon Pharma is excited to announce the launch, for the first time in India, of a groundbreaking pharmaceutical drug combination for type 2 diabetes management.


Key Target Audience
Diabetes Treatment Providers, Diabetes Device Manufacturers, Diabetes Drug Manufacturers, Government Associations and Agencies, Private Research Organizations, Potential Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes

By Device Type
  • Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors)
  • Insulin Delivery Device (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Others)

By Treatment Type
  • Insulin
  • Oral Hypoglycaemic Drugs
  • Non-Insulin Injectable Drugs
  • Other

By Diabetes Test Type
  • Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test)
  • Urine Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Government Initiatives for Providing Diabetes Cure Treatment across the Globe
      • 3.2.2. Rising Demand for Fast, Safe and Better Diabetes Care Products from Highly Populated Countries such as China and India
    • 3.3. Market Challenges
      • 3.3.1. Adverse Effects Associated with Diabetes Care Devices
    • 3.4. Market Trends
      • 3.4.1. Increasing Population Suffering from Diabetes due to Sedentary Lifestyle and Increasing Obese Population across the Globe
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetes Treatment, by Diabetes Type, Device Type, Treatment Type, Diabetes Test Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Diabetes Treatment (Value)
      • 5.2.1. Global Diabetes Treatment by: Diabetes Type (Value)
        • 5.2.1.1. Type 1 Diabetes
        • 5.2.1.2. Type 2 Diabetes
      • 5.2.2. Global Diabetes Treatment by: Device Type (Value)
        • 5.2.2.1. Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors)
        • 5.2.2.2. Insulin Delivery Device (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Others)
      • 5.2.3. Global Diabetes Treatment by: Treatment Type (Value)
        • 5.2.3.1. Insulin
        • 5.2.3.2. Oral Hypoglycaemic Drugs
        • 5.2.3.3. Non-Insulin Injectable Drugs
        • 5.2.3.4. Other
      • 5.2.4. Global Diabetes Treatment by: Diabetes Test Type (Value)
        • 5.2.4.1. Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test)
        • 5.2.4.2. Urine Test
      • 5.2.5. Global Diabetes Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Diabetes Treatment (Price)
  • 6. Diabetes Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lily & Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca Plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lifescan (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Terumo Medical Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Holding AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ascensia Diabetes Care Holdings AG (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Becton Dickinson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Diabetes Treatment Sale, by Diabetes Type, Device Type, Treatment Type, Diabetes Test Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Diabetes Treatment (Value)
      • 7.2.1. Global Diabetes Treatment by: Diabetes Type (Value)
        • 7.2.1.1. Type 1 Diabetes
        • 7.2.1.2. Type 2 Diabetes
      • 7.2.2. Global Diabetes Treatment by: Device Type (Value)
        • 7.2.2.1. Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors)
        • 7.2.2.2. Insulin Delivery Device (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Others)
      • 7.2.3. Global Diabetes Treatment by: Treatment Type (Value)
        • 7.2.3.1. Insulin
        • 7.2.3.2. Oral Hypoglycaemic Drugs
        • 7.2.3.3. Non-Insulin Injectable Drugs
        • 7.2.3.4. Other
      • 7.2.4. Global Diabetes Treatment by: Diabetes Test Type (Value)
        • 7.2.4.1. Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test)
        • 7.2.4.2. Urine Test
      • 7.2.5. Global Diabetes Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Diabetes Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetes Treatment: by Diabetes Type(USD Million)
  • Table 2. Diabetes Treatment Type 1 Diabetes , by Region USD Million (2018-2023)
  • Table 3. Diabetes Treatment Type 2 Diabetes , by Region USD Million (2018-2023)
  • Table 4. Diabetes Treatment: by Device Type(USD Million)
  • Table 5. Diabetes Treatment Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors) , by Region USD Million (2018-2023)
  • Table 6. Diabetes Treatment Insulin Delivery Device (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Others) , by Region USD Million (2018-2023)
  • Table 7. Diabetes Treatment: by Treatment Type(USD Million)
  • Table 8. Diabetes Treatment Insulin , by Region USD Million (2018-2023)
  • Table 9. Diabetes Treatment Oral Hypoglycaemic Drugs , by Region USD Million (2018-2023)
  • Table 10. Diabetes Treatment Non-Insulin Injectable Drugs , by Region USD Million (2018-2023)
  • Table 11. Diabetes Treatment Other , by Region USD Million (2018-2023)
  • Table 12. Diabetes Treatment: by Diabetes Test Type(USD Million)
  • Table 13. Diabetes Treatment Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test) , by Region USD Million (2018-2023)
  • Table 14. Diabetes Treatment Urine Test , by Region USD Million (2018-2023)
  • Table 15. South America Diabetes Treatment, by Country USD Million (2018-2023)
  • Table 16. South America Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 17. South America Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 18. South America Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 19. South America Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 20. Brazil Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 21. Brazil Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 22. Brazil Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 23. Brazil Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 24. Argentina Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 25. Argentina Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 26. Argentina Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 27. Argentina Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 28. Rest of South America Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 29. Rest of South America Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 30. Rest of South America Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 31. Rest of South America Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 32. Asia Pacific Diabetes Treatment, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 34. Asia Pacific Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 35. Asia Pacific Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 36. Asia Pacific Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 37. China Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 38. China Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 39. China Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 40. China Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 41. Japan Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 42. Japan Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 43. Japan Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 44. Japan Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 45. India Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 46. India Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 47. India Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 48. India Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 49. South Korea Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 50. South Korea Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 51. South Korea Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 52. South Korea Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 53. Taiwan Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 54. Taiwan Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 55. Taiwan Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 56. Taiwan Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 57. Australia Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 58. Australia Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 59. Australia Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 60. Australia Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 65. Europe Diabetes Treatment, by Country USD Million (2018-2023)
  • Table 66. Europe Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 67. Europe Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 68. Europe Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 69. Europe Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 70. Germany Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 71. Germany Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 72. Germany Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 73. Germany Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 74. France Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 75. France Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 76. France Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 77. France Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 78. Italy Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 79. Italy Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 80. Italy Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 81. Italy Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 82. United Kingdom Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 83. United Kingdom Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 84. United Kingdom Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 85. United Kingdom Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 86. Netherlands Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 87. Netherlands Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 88. Netherlands Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 89. Netherlands Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 90. Rest of Europe Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 91. Rest of Europe Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 92. Rest of Europe Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 93. Rest of Europe Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 94. MEA Diabetes Treatment, by Country USD Million (2018-2023)
  • Table 95. MEA Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 96. MEA Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 97. MEA Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 98. MEA Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 99. Middle East Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 100. Middle East Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 101. Middle East Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 102. Middle East Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 103. Africa Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 104. Africa Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 105. Africa Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 106. Africa Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 107. North America Diabetes Treatment, by Country USD Million (2018-2023)
  • Table 108. North America Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 109. North America Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 110. North America Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 111. North America Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 112. United States Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 113. United States Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 114. United States Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 115. United States Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 116. Canada Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 117. Canada Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 118. Canada Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 119. Canada Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 120. Mexico Diabetes Treatment, by Diabetes Type USD Million (2018-2023)
  • Table 121. Mexico Diabetes Treatment, by Device Type USD Million (2018-2023)
  • Table 122. Mexico Diabetes Treatment, by Treatment Type USD Million (2018-2023)
  • Table 123. Mexico Diabetes Treatment, by Diabetes Test Type USD Million (2018-2023)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Diabetes Treatment: by Diabetes Type(USD Million)
  • Table 135. Diabetes Treatment Type 1 Diabetes , by Region USD Million (2025-2030)
  • Table 136. Diabetes Treatment Type 2 Diabetes , by Region USD Million (2025-2030)
  • Table 137. Diabetes Treatment: by Device Type(USD Million)
  • Table 138. Diabetes Treatment Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets, Continuous Glucose Monitors) , by Region USD Million (2025-2030)
  • Table 139. Diabetes Treatment Insulin Delivery Device (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Others) , by Region USD Million (2025-2030)
  • Table 140. Diabetes Treatment: by Treatment Type(USD Million)
  • Table 141. Diabetes Treatment Insulin , by Region USD Million (2025-2030)
  • Table 142. Diabetes Treatment Oral Hypoglycaemic Drugs , by Region USD Million (2025-2030)
  • Table 143. Diabetes Treatment Non-Insulin Injectable Drugs , by Region USD Million (2025-2030)
  • Table 144. Diabetes Treatment Other , by Region USD Million (2025-2030)
  • Table 145. Diabetes Treatment: by Diabetes Test Type(USD Million)
  • Table 146. Diabetes Treatment Blood Test (A1c Test, Random Blood Sugar Test, Fasting blood sugar test, Oral glucose tolerance test) , by Region USD Million (2025-2030)
  • Table 147. Diabetes Treatment Urine Test , by Region USD Million (2025-2030)
  • Table 148. South America Diabetes Treatment, by Country USD Million (2025-2030)
  • Table 149. South America Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 150. South America Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 151. South America Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 152. South America Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 153. Brazil Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 154. Brazil Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 155. Brazil Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 156. Brazil Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 157. Argentina Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 158. Argentina Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 159. Argentina Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 160. Argentina Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 161. Rest of South America Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 162. Rest of South America Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 163. Rest of South America Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 164. Rest of South America Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 165. Asia Pacific Diabetes Treatment, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 167. Asia Pacific Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 168. Asia Pacific Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 169. Asia Pacific Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 170. China Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 171. China Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 172. China Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 173. China Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 174. Japan Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 175. Japan Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 176. Japan Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 177. Japan Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 178. India Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 179. India Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 180. India Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 181. India Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 182. South Korea Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 183. South Korea Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 184. South Korea Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 185. South Korea Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 186. Taiwan Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 187. Taiwan Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 188. Taiwan Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 189. Taiwan Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 190. Australia Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 191. Australia Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 192. Australia Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 193. Australia Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 198. Europe Diabetes Treatment, by Country USD Million (2025-2030)
  • Table 199. Europe Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 200. Europe Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 201. Europe Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 202. Europe Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 203. Germany Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 204. Germany Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 205. Germany Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 206. Germany Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 207. France Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 208. France Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 209. France Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 210. France Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 211. Italy Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 212. Italy Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 213. Italy Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 214. Italy Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 215. United Kingdom Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 216. United Kingdom Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 217. United Kingdom Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 218. United Kingdom Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 219. Netherlands Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 220. Netherlands Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 221. Netherlands Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 222. Netherlands Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 223. Rest of Europe Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 224. Rest of Europe Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 225. Rest of Europe Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 226. Rest of Europe Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 227. MEA Diabetes Treatment, by Country USD Million (2025-2030)
  • Table 228. MEA Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 229. MEA Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 230. MEA Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 231. MEA Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 232. Middle East Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 233. Middle East Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 234. Middle East Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 235. Middle East Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 236. Africa Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 237. Africa Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 238. Africa Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 239. Africa Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 240. North America Diabetes Treatment, by Country USD Million (2025-2030)
  • Table 241. North America Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 242. North America Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 243. North America Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 244. North America Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 245. United States Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 246. United States Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 247. United States Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 248. United States Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 249. Canada Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 250. Canada Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 251. Canada Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 252. Canada Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 253. Mexico Diabetes Treatment, by Diabetes Type USD Million (2025-2030)
  • Table 254. Mexico Diabetes Treatment, by Device Type USD Million (2025-2030)
  • Table 255. Mexico Diabetes Treatment, by Treatment Type USD Million (2025-2030)
  • Table 256. Mexico Diabetes Treatment, by Diabetes Test Type USD Million (2025-2030)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetes Treatment: by Diabetes Type USD Million (2018-2023)
  • Figure 5. Global Diabetes Treatment: by Device Type USD Million (2018-2023)
  • Figure 6. Global Diabetes Treatment: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Diabetes Treatment: by Diabetes Test Type USD Million (2018-2023)
  • Figure 8. South America Diabetes Treatment Share (%), by Country
  • Figure 9. Asia Pacific Diabetes Treatment Share (%), by Country
  • Figure 10. Europe Diabetes Treatment Share (%), by Country
  • Figure 11. MEA Diabetes Treatment Share (%), by Country
  • Figure 12. North America Diabetes Treatment Share (%), by Country
  • Figure 13. Global Diabetes Treatment share by Players 2023 (%)
  • Figure 14. Global Diabetes Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Diabetes Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 21. Eli Lily & Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lily & Company (United States) Revenue: by Geography 2023
  • Figure 23. Medtronic (United States) Revenue, Net Income and Gross profit
  • Figure 24. Medtronic (United States) Revenue: by Geography 2023
  • Figure 25. AstraZeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Lifescan (United States) Revenue, Net Income and Gross profit
  • Figure 28. Lifescan (United States) Revenue: by Geography 2023
  • Figure 29. Terumo Medical Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Terumo Medical Corporation (Japan) Revenue: by Geography 2023
  • Figure 31. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Ascensia Diabetes Care Holdings AG (United States) Revenue, Net Income and Gross profit
  • Figure 34. Ascensia Diabetes Care Holdings AG (United States) Revenue: by Geography 2023
  • Figure 35. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Becton Dickinson (United States) Revenue: by Geography 2023
  • Figure 37. Global Diabetes Treatment: by Diabetes Type USD Million (2025-2030)
  • Figure 38. Global Diabetes Treatment: by Device Type USD Million (2025-2030)
  • Figure 39. Global Diabetes Treatment: by Treatment Type USD Million (2025-2030)
  • Figure 40. Global Diabetes Treatment: by Diabetes Test Type USD Million (2025-2030)
  • Figure 41. South America Diabetes Treatment Share (%), by Country
  • Figure 42. Asia Pacific Diabetes Treatment Share (%), by Country
  • Figure 43. Europe Diabetes Treatment Share (%), by Country
  • Figure 44. MEA Diabetes Treatment Share (%), by Country
  • Figure 45. North America Diabetes Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Eli Lily & Company (United States)
  • Medtronic (United States)
  • AstraZeneca Plc. (United Kingdom)
  • Lifescan (United States)
  • Terumo Medical Corporation (Japan)
  • Roche Holding AG (Switzerland)
  • Ascensia Diabetes Care Holdings AG (United States)
  • Becton Dickinson (United States)
Additional players considered in the study are as follows:
Dexcom (United States) , ARKRAY Healthcare Pvt. Ltd. (India) , B. Braun Melsungen (Germany) , Terumo Corporation (Japan)
Select User Access Type

Key Highlights of Report


Apr 2024 204 Pages 80 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetes Treatment Market Quantitative research analysis
Global Diabetes Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Bayer AG (Germany), Eli Lily & Company (United States), Medtronic (United States), AstraZeneca Plc. (United Kingdom), Lifescan (United States), Terumo Medical Corporation (Japan), Roche Holding AG (Switzerland), Ascensia Diabetes Care Holdings AG (United States) and Becton Dickinson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Population Suffering from Diabetes due to Sedentary Lifestyle and Increasing Obese Population across the Globe" is seen as one of major influencing trends for Diabetes Treatment Market during projected period 2023-2030.
The Diabetes Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Diabetes Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Medical Device Cleaning Services Comprehensive Study by Type (Manual Cleaning, Automatic Cleaning), Application (Hospitals, Clinics, Diagnostic Centers, Other), Process (Cleaning, Disinfecting, Steri...
$ 3500
Wound Irrigation Solution Comprehensive Study by Type (Wetting Agents, Antiseptics, Others), Distribution Channel (Online, Offline), End User (Hospitals, Ambulatory Surgical Centers, Clinics, Long Te...
$ 3350
Specialty Hospitals Comprehensive Study by Type (Cancer Hospitals, Cardiac Hospitals, Rehabilitation Hospitals, ENT Hospitals, Neurology Hospitals, Orthopedic Hospitals, Others), Application (Men, Wo...
$ 3750
Bile Duct Cancer Comprehensive Study by Type (Intrahepatic, Perihilar (also called hilar), Distal), Application (Hospitals, Clinics, Other), Stages types (Stage 0, Stage I (IA , IB), Stage II, Stage ...
$ 3650
Drug of Abuse (DOA) Testing Comprehensive Study by Type (Rapid Test Kits, Assay Kits & Reagents, Immunoassay Analyzers, Others), End-users (Hospitals, Laboratories, At-Home, Others), Test (Onsite Scr...
$ 3800
Cancer Tumor Profiling Comprehensive Study by Type (Breast Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Others (Melanoma, Colorectal, Bladder, Leukemia)), Application (Clinica...
$ 3750